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A new type of pneumonia with an unknown causative agent broke out in Wuhan, Hubei province, China in late December 1, 2019.[^1^](#tan13941-bib-0001){ref-type="ref"}, [^2^](#tan13941-bib-0002){ref-type="ref"} A novel coronavirus was subsequently confirmed as the agent causing the disease.[^1^](#tan13941-bib-0001){ref-type="ref"}, [^2^](#tan13941-bib-0002){ref-type="ref"} The novel coronavirus was named 2019‐nCoV by the World Health Organization (WHO) on January 12, 2020, and was later named severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) by the International Classification Committee of Viruses on February 11, 2020.[^3^](#tan13941-bib-0003){ref-type="ref"}, [^4^](#tan13941-bib-0004){ref-type="ref"} Now, the associated disease has been named coronavirus disease 2019 (COVID‐19) by the WHO.[^3^](#tan13941-bib-0003){ref-type="ref"}, [^4^](#tan13941-bib-0004){ref-type="ref"} The transmission mode for COVID‐19 has been shown to be human to human.[^3^](#tan13941-bib-0003){ref-type="ref"} COVID‐19 is currently a global pandemic, and over 2 740 000 cases of COVID‐2019 and 191 000 deaths have been reported globally as of April 24, 2020. The HLA system participates in immune regulation in humans and it plays an important role in the occurrence and development of infectious diseases.[^5^](#tan13941-bib-0005){ref-type="ref"}, [^6^](#tan13941-bib-0006){ref-type="ref"}, [^7^](#tan13941-bib-0007){ref-type="ref"} Chen et al reported an odds ratio of 4.*4* for SARS‐CoV infection in individuals homozygous or heterozygous for *HLA‐C\*08:01*.[^7^](#tan13941-bib-0007){ref-type="ref"} We hypothesized that HLA variation in the population may be associated with the occurrence of COVID‐19, because HLA plays a pivotal role in the immune response to pathogens. Here, we report HLA allele frequencies in Chinese Han individuals with COVID‐19 and a comparison between HLA allele distribution in COVID‐19 patients and healthy individuals.

Eighty‐two Han individuals from Zhejiang with confirmed COVID‐19 were tested. All patients had mild or severe COVID‐19, with none in a critical condition. Individuals were recruited for plasma donation after recovery and the plasma was used for treatment of other COVID‐19 patients with severe or critical symptoms. The ages of the individuals ranged from 20 to 54. All samples were collected during the plasma donation process and informed consent was obtained from all individuals. The samples were genotyped at the HLA‐A, ‐B, ‐C, ‐DRB1, ‐DRB3/4/5, ‐DQA1, ‐DQB1, ‐DPA1, and ‐DPB1 loci by NGS‐based typing, using an AllType NGS 9‐Loci Amplification Kit (One Lambda Inc., Canoga Park, California), according to the manufacturer\'s instructions. HLA genotypes were assigned using TypeStream Visual Software version 2.0 (One Lambda Inc.). The Chinese HLA common and well‐documented principle was used to solve ambiguous HLA allele combination assignments.[^8^](#tan13941-bib-0008){ref-type="ref"} Hardy‐Weinberg equilibrium (HWE) was assessed by maximum likelihood, using the method of Guo and Thompson, which has been implemented in Arlequin version 3.5.[^9^](#tan13941-bib-0009){ref-type="ref"} Odds ratios (95% confidence interval \[CI\]) and *P*‐values were calculated using Fisher\'s exact test or Yates continuity‐corrected χ^2^ test in Prism 5.0 software (GraphPad, San Diego, California). Corrected *P*‐values (*P*c) were obtained by multiplying the number of alleles at each locus using the Benjamini‐Hochberg method. The significance of the *P*c‐value was set at a level of .05.

The results of HLA‐A, ‐B, ‐C, ‐DRB1, ‐DRB3/4/5, ‐DQA1, ‐DQB1, ‐DPA1, and ‐DPB1 genotyping were fitted for HWE after considering the *P*c‐value (Table [S1](#tan13941-supitem-0001){ref-type="supplementary-material"}). The rates of ambiguous HLA allele combinations for HLA‐A, ‐B, ‐C, ‐DRB1, ‐DRB3/4/5,‐DQA1, ‐DQB1, ‐DPA1, and ‐DPB1 loci were 1.22%, 3.66%, 3.66%, 47.56%, 6.10%, 1.22%, 47.56%, 1.22%, and 46.34%, respectively. The number of alleles at the HLA‐A, ‐C, ‐B, ‐DRB1, ‐DRB3/4/5, ‐DQA1 ‐DQB1, ‐DPA1, and ‐DPB1 loci were 15, 20, 30, 25, 9, 13, 14, 5, and 15, respectively ([Table S2](#tan13941-supitem-0001){ref-type="supplementary-material"}). The allele distributions of HLA‐A, ‐C, ‐B, ‐DRB1, ‐DQB1, and ‐DPB1 loci were compared between COVID‐19 patients and control individuals. The resulting ORs (95% CI) and *P*‐values are presented in [Table S2](#tan13941-supitem-0001){ref-type="supplementary-material"}. Data for control individuals were obtained from our previous studies of bone marrow donors in the Zhejiang Han population.[^10^](#tan13941-bib-0010){ref-type="ref"}, [^11^](#tan13941-bib-0011){ref-type="ref"} There were 3548 individuals in the control group with genotyping data for the HLA‐A, ‐B, ‐C, ‐DRB1,‐DQB1 loci, and 242 with data for HLA‐DPB1 locus.[^10^](#tan13941-bib-0010){ref-type="ref"}, [^11^](#tan13941-bib-0011){ref-type="ref"} HLA genotyping of the control individuals was performed using polymerase chain reaction at two‐field resolution, as in our previous reports.[^10^](#tan13941-bib-0010){ref-type="ref"}, [^11^](#tan13941-bib-0011){ref-type="ref"} The frequencies and ORs of the HLA alleles, with uncorrected significance, for COVID‐19 patients are listed in Table [1](#tan13941-tbl-0001){ref-type="table"}. *HLA‐C\*07:29*, *C\*08:01G* (including *C\*08:01* and *C\*08:22*), *B\*15:27*, *B\*40:06*, *DRB1\*04:06*, and *DPB1\*36:01* frequencies were higher in COVID‐19 patients than in the control population, with uncorrected statistical significance (*P* \< .05). The ORs were 130.20, 1.65, 3.59, 2.43, 2.39, and 12.08, respectively. Meanwhile, the frequencies of the *DRB1\*12:02* and *DPB1\*04:01* alleles were significantly lower in COVID‐19 patients (*Pc* \< .05), with ORs of 0.44 and 0.40, respectively. However, only the frequencies of *HLA‐C\*07:29* and *B\*15:27* remained significantly different after *P*‐value correction. The *HLA‐C\*07:29* allele is a well‐documented allele in the Chinese population, with five cases in the 816 486 bone marrow donors.[^8^](#tan13941-bib-0008){ref-type="ref"} In the present study, *HLA‐C\*07:29* was found in one COVID‐19 patient, but in no individuals in the control group. Therefore, the significance of *C\*07:29* should be interpreted with caution and this result needs to be confirmed in further studies with larger sample sizes.

###### 

The frequency and odds ratio values of the HLA alleles with uncorrected significant in COVID‐19 individuals

  Allele          COVID‐19   Control group                                                 
  --------------- ---------- --------------- ----- ------- -------------------- ---------- ----------
  *C\*07:29*      1          0.61            0     0       130.20 (5.28‐3211)   **.001**   **.025**
  *C\*08:01G\#*   23         14.02           640   9.02    1.65 (1.05‐2.58)     .039       .371
  *B\*15:27*      8          4.88            100   1.41    3.59 (1.72‐7.50)     **.001**   **.030**
  *B\*40:06*      11         6.71            204   2.87    2.43 (1.30‐4.55)     .009       .129
  *DRB1\*04:06*   12         7.32            227   3.20    2.39 (1.3‐4.36)      .007       .173
  *DRB1\*12:02*   8          4.88            750   10.57   0.43 (0.21‐0.89)     .026       .324
  *DPB1\*04:01*   8          4.88            55    11.36   0.40 (0.19‐0.86)     .023       .174
  *DPB1\*36:01*   4          2.44            1     0.21    12.08 (1.34‐108.9)   .021       .174

*Note*: *\#C\*08:01G ( 9.02%)* was included *C\*08:01* and *C\*08:22*. The number of the individuals in the control group were 3548 for HLA‐B, ‐C, ‐DRB1 loci, and 242 for HLA‐DPB1 locus.

Two alleles, *B\*07:02* (1.38%) and *B\*27:04* (1.92%), with frequencies greater than 1% in the control group, were not found in COVID‐19 patients. The odds ratios for *B\*07:02* and *B\*27:04* were 0.216 (95% CI: 0.01335‐3.494, *P =* .2408) and 0.155 (95% CI: 0.009598‐2.503, *P* = .134). Because there were no data for HLA‐DRB3/4/5, ‐DQA1, or ‐DPA1 loci in the control group,[^10^](#tan13941-bib-0010){ref-type="ref"}, [^11^](#tan13941-bib-0011){ref-type="ref"} the allele frequencies of these loci could not be compared between the two groups. The allele frequency data for the HLA‐DRB3/4/5, ‐DQA1, and ‐DPA1 loci are summarized in [Table S3](#tan13941-supitem-0001){ref-type="supplementary-material"}.

The HLA system is an important host genetic factor that plays an important role in determining the outcome of many infectious diseases, including human immunodeficiency virus (HIV) and severe acute respiratory syndrome (SARS).[^6^](#tan13941-bib-0006){ref-type="ref"}, [^12^](#tan13941-bib-0012){ref-type="ref"}, [^13^](#tan13941-bib-0013){ref-type="ref"} Associations between HLAs and the development and/or severity of SARS have been found in some populations.[^7^](#tan13941-bib-0007){ref-type="ref"}, [^13^](#tan13941-bib-0013){ref-type="ref"}, [^14^](#tan13941-bib-0014){ref-type="ref"} *HLA‐B\*07:03*, *B\*46:01*, *DRB1\*03:01*, *DRB1\*12:02* alleles have been reported to be associated with susceptibility to SARS, but some studies have not confirmed these results.[^15^](#tan13941-bib-0015){ref-type="ref"} The sequence of SARS‐CoV‐2 shows some homology with SARS‐CoV, but there are distinct differences between the two viruses.[^4^](#tan13941-bib-0004){ref-type="ref"} Therefore, the association of HLA alleles with COVID‐19 warrants further research.[^15^](#tan13941-bib-0015){ref-type="ref"}, [^16^](#tan13941-bib-0016){ref-type="ref"} In the present study, these SARS‐susceptibility alleles were not found to occur at a significantly different frequency in COVID‐19 patients after *P*‐value correction. Nguyen et al[^16^](#tan13941-bib-0016){ref-type="ref"} predicted the binding affinity of SARS‐CoV‐2 to 145 HLA class I alleles, and *HLA‐A\*02:02*, *HLA‐B\*15:03*, and *HLA‐C\*12:03* were found to be the top presenters of conserved peptides. We found that *B\*15:27* alleles may be associated with the occurrence of COVID‐19. *HLA‐B\*15:03* and *B\*15:27* belong to the *B\*15* group and have 10 nucleotide differences. Prediction of the peptide‐binding groove of these alleles may help to explain their association with COVID‐19. Although the number of samples in the present study was small, these data will still be useful for exploring the influence of HLA gene polymorphisms on susceptibility to COVID‐19 and patient outcomes.
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